GlassScriptPhysician profile
Polina Manesis
NPI 1518252741
$8,420.31
in general payments reported to CMS, 2019-2025
30 companies · $38.47 in 2025
The $38.47 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,515 · 2022: $2,690 · 2023: $3,414 · 2024: $763 · 2025: $38.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,139.86 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,787.05 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,225.41 | 2021-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,036.48 | 2021-2024 | Stelara |
| Janssen Scientific Affairs, LLC | $457.80 | 2021-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $447.47 | 2021-2024 | Entyvio, Gattex |
| Ardelyx, INC. | $445.15 | 2022-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $414.21 | 2021-2024 | Rebyota, Cimzia |
| Genzyme Corporation | $363.36 | 2022-2024 | |
| Redhill Biopharma INC. | $340.24 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Nestle Healthcare Nutrition INC. | $279.33 | 2021-2023 | |
| Gilead Sciences, INC. | $223.20 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $179.27 | 2022-2024 | Dupixent |
| Celgene Corporation | $171.80 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $148.05 | 2023 | Ocaliva |
| Incyte Corporation | $129.37 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $123.49 | 2023-2024 | Cologuard Collection Kit |
| Olympus America INC. | $86.84 | 2022 | |
| Novo Nordisk INC | $71.97 | 2021-2024 | Ozempic |
| Qol Medical, LLC | $69.23 | 2022 | |
| Lilly USA, LLC | $63.64 | 2023-2024 | Omvoh |
| Mallinckrodt Hospital Products INC. | $61.86 | 2023-2024 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $58.10 | 2024 | Voquezna |
| Vivus LLC | $55.39 | 2021-2023 | Qsymia |
| Aimmune Therapeutics, INC. | $47.08 | 2023-2024 | |
| Evoke Pharma, INC. | $36.31 | 2023 | Gimoti |
| Pfizer INC. | $21.53 | 2023 | |
| Medtronic, INC. | $20.00 | 2021 | |
| Ironwood Pharmaceuticals, INC | $19.04 | 2022 | |
| Merck Sharp & Dohme LLC | $18.86 | 2024 | Dificid |
| Braintree Laboratories, INC. | $18.78 | 2023 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Polina Manesis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.